Date: 2016-04-11
Type of information: Nomination
Compound:
Company: Diamyd Medical (Sweden)
Therapeutic area: Autoimmune diseases - Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 11, 2016, Diamyd Medical announced that the Company’s Board of Directors has appointed Ulf Hannelius, PhD, MBA, to new CEO. Ulf Hannelius (40), PhD in molecular biology from Karolinska Institute and with an MBA from Stockholm School of Economics has been appointed to, and today assumes, the position as CEO of Diamyd Medical.
Financial terms:
Latest news:
